| Dr Hashmukh R Patel, MD | |
|
55 Meadowlands Pkwy, Secaucus, NJ 07094-2977 | |
| (201) 392-3332 | |
| Not Available |
| Full Name | Dr Hashmukh R Patel |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 39 Years |
| Location | 55 Meadowlands Pkwy, Secaucus, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881895001 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA05821800 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Meridian Hospice | Neptune, NJ | Hospice |
| Bayshore Medical Center | Holmdel, NJ | Hospital |
| Jfk Medical Center | Edison, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alteon Health New Jersey Hm Pc | 2769714302 | 26 |
News Archive
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
› Verified 6 days ago
| Entity Name | North Haledon Medical, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624088 PECOS PAC ID: 0345299947 Enrollment ID: O20050121000032 |
News Archive
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
› Verified 6 days ago
| Entity Name | Two River Physician Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417354333 PECOS PAC ID: 0648594820 Enrollment ID: O20150116000462 |
News Archive
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
› Verified 6 days ago
| Entity Name | Holmdel Physician Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346647328 PECOS PAC ID: 7517282890 Enrollment ID: O20150209000024 |
News Archive
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
› Verified 6 days ago
| Entity Name | Liberty Med Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366983033 PECOS PAC ID: 7416234075 Enrollment ID: O20170509000044 |
News Archive
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
› Verified 6 days ago
| Entity Name | Alteon Health New Jersey Hm Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285284091 PECOS PAC ID: 2769714302 Enrollment ID: O20191030003270 |
News Archive
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hashmukh R Patel, MD 55 Azalea Pl, Piscataway, NJ 08854-7500 Ph: (732) 537-9541 | Dr Hashmukh R Patel, MD 55 Meadowlands Pkwy, Secaucus, NJ 07094-2977 Ph: (201) 392-3332 |
News Archive
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."
› Verified 6 days ago
Wayne D Siegel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 Route 3 Ste 204, Secaucus, NJ 07094 Phone: 201-866-2400 Fax: 201-866-0444 | |
Dr. Grace Haechung Yang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 38 Meadowlands Pkwy, Secaucus, NJ 07094 Phone: 201-293-0401 Fax: 201-293-0402 | |
Robert Wayne Boyajian, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 State Rt 3, Suite 203, Secaucus, NJ 07094 Phone: 201-865-3100 Fax: 201-865-8311 | |
Dr. Jihad S Moukdad, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1265 Paterson Plank Rd, Secaucus, NJ 07094 Phone: 201-223-1121 Fax: 201-223-1126 | |
Amanda Moukdad, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1265 Paterson Plank Rd Ste 3b, Secaucus, NJ 07094 Phone: 201-223-1121 | |
Dr. Mary Nadratowski, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 9 Green Valley Ct, Secaucus, NJ 07094 Phone: 201-865-8120 Fax: 973-235-6228 | |
Dr. Kunal Manmohan Patel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1265 Paterson Plank Rd Ste 2e, Secaucus, NJ 07094 Phone: 201-866-7000 Fax: 201-866-7800 |